KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Accounts Payables (2016 - 2025)

AbbVie (ABBV) has disclosed Accounts Payables for 14 consecutive years, with $34.7 billion as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 8.73% to $34.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $34.7 billion through Dec 2025, up 8.73% year-over-year, with the annual reading at $34.7 billion for FY2025, 8.73% up from the prior year.
  • Accounts Payables for Q4 2025 was $34.7 billion at AbbVie, up from $33.6 billion in the prior quarter.
  • The five-year high for Accounts Payables was $34.7 billion in Q4 2025, with the low at $20.6 billion in Q1 2021.
  • Average Accounts Payables over 5 years is $27.3 billion, with a median of $28.2 billion recorded in 2023.
  • The sharpest move saw Accounts Payables skyrocketed 62.12% in 2021, then fell 0.91% in 2025.
  • Over 5 years, Accounts Payables stood at $22.7 billion in 2021, then grew by 11.91% to $25.4 billion in 2022, then grew by 20.66% to $30.6 billion in 2023, then grew by 4.23% to $31.9 billion in 2024, then grew by 8.73% to $34.7 billion in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $34.7 billion, $33.6 billion, and $32.2 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.